today announced the presentation of preclinical and translational pharmacokinetics (PK) data of GD2-SADA in a poster at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) Mid-Winter and ...

Adial Pharmaceuticals announced completion of PK study for AD04, confirming predictable bioavailability, dose proportionality ...

Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and ...

(RTTNews) - Adial Pharmaceuticals, Inc. (ADIL), Wednesday revealed positive results from its pharmacokinetics study of AD04 for the treatment of Alcohol Use Disorder in patients with a 5-HT3 genomic ...

AceLink Therapeutics, Inc., a clinical-stage biotech company developing next-generation oral substrate reduction therapies (SRTs), presented interim d ...

Adial Pharmaceuticals has completed a pharmacokinetics study of its investigational drug AD04, aimed at treating Alcohol Use Disorder (AUD) in patients with a specific genomic biomarker.

Insilico Medicine (“Insilico”) announces that the team, with the support of its generative chemistry engine, has developed a ...

(RTTNews) - Y-mAbs Therapeutics, Inc. (YMAB), a commercial-stage biopharmaceutical company presented preclinical and translational pharmacokinetics or PK data of GD2-SADA at the 2025 SNMMI Mid ...

The FDA has approved Avtozma® (tocilizumab-anoh), a biosimilar to Actemra®, in both intravenous and subcutaneous formulations.

Tonix Pharmaceuticals has reported positive topline outcomes from its Phase I single ascending dose study of its ...